BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
1987
159
LTM Revenue $90.1M
LTM EBITDA $18.4M
$1.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BioLife Solutions has a last 12-month revenue (LTM) of $90.1M and a last 12-month EBITDA of $18.4M.
In the most recent fiscal year, BioLife Solutions achieved revenue of $82.3M and an EBITDA of $1.5M.
BioLife Solutions expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See BioLife Solutions valuation multiples based on analyst estimatesLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue | $90.1M | XXX | $82.3M | XXX | XXX | XXX |
Gross Profit | $53.6M | XXX | $53.7M | XXX | XXX | XXX |
Gross Margin | 60% | XXX | 65% | XXX | XXX | XXX |
EBITDA | $18.4M | XXX | $1.5M | XXX | XXX | XXX |
EBITDA Margin | 20% | XXX | 2% | XXX | XXX | XXX |
EBIT | -$5.6M | XXX | -$7.1M | XXX | XXX | XXX |
EBIT Margin | -6% | XXX | -9% | XXX | XXX | XXX |
Net Profit | -$7.8M | XXX | -$20.2M | XXX | XXX | XXX |
Net Margin | -9% | XXX | -25% | XXX | XXX | XXX |
Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 4, 2025, BioLife Solutions's stock price is $23.
BioLife Solutions has current market cap of $1.1B, and EV of $1.0B.
See BioLife Solutions trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$1.0B | $1.1B | XXX | XXX | XXX | XXX | $-0.16 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 4, 2025, BioLife Solutions has market cap of $1.1B and EV of $1.0B.
BioLife Solutions's trades at 12.5x EV/Revenue multiple, and 668.8x EV/EBITDA.
Equity research analysts estimate BioLife Solutions's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioLife Solutions has a P/E ratio of -139.8x.
See valuation multiples for BioLife Solutions and 12K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Market cap (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
EV (current) | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
EV/Revenue | 11.4x | XXX | 12.5x | XXX | XXX | XXX |
EV/EBITDA | 55.6x | XXX | 668.8x | XXX | XXX | XXX |
EV/EBIT | -183.3x | XXX | -143.7x | XXX | XXX | XXX |
EV/Gross Profit | 19.1x | XXX | n/a | XXX | XXX | XXX |
P/E | -139.8x | XXX | -53.8x | XXX | XXX | XXX |
EV/FCF | 138.0x | XXX | 208.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBioLife Solutions's last 12 month revenue growth is 18%
BioLife Solutions's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.4M for the same period.
BioLife Solutions's rule of 40 is -13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BioLife Solutions's rule of X is 66% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BioLife Solutions and other 12K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue Growth | 18% | XXX | 18% | XXX | XXX | XXX |
EBITDA Margin | 20% | XXX | 2% | XXX | XXX | XXX |
EBITDA Growth | 38% | XXX | n/a | XXX | XXX | XXX |
Rule of 40 | -13% | XXX | 20% | XXX | XXX | XXX |
Bessemer Rule of X | XXX | XXX | 66% | XXX | XXX | XXX |
Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
S&M Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
Opex to Revenue | XXX | XXX | 74% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioLife Solutions acquired XXX companies to date.
Last acquisition by BioLife Solutions was XXXXXXXX, XXXXX XXXXX XXXXXX . BioLife Solutions acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free TrialWhen was BioLife Solutions founded? | BioLife Solutions was founded in 1987. |
Where is BioLife Solutions headquartered? | BioLife Solutions is headquartered in United States of America. |
How many employees does BioLife Solutions have? | As of today, BioLife Solutions has 159 employees. |
Who is the CEO of BioLife Solutions? | BioLife Solutions's CEO is Mr. Roderick De Greef. |
Is BioLife Solutions publicy listed? | Yes, BioLife Solutions is a public company listed on NAS. |
What is the stock symbol of BioLife Solutions? | BioLife Solutions trades under BLFS ticker. |
When did BioLife Solutions go public? | BioLife Solutions went public in 1989. |
Who are competitors of BioLife Solutions? | Similar companies to BioLife Solutions include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
What is the current market cap of BioLife Solutions? | BioLife Solutions's current market cap is $1.1B |
What is the current revenue of BioLife Solutions? | BioLife Solutions's last 12 months revenue is $90.1M. |
What is the current revenue growth of BioLife Solutions? | BioLife Solutions revenue growth (NTM/LTM) is 18%. |
What is the current EV/Revenue multiple of BioLife Solutions? | Current revenue multiple of BioLife Solutions is 11.4x. |
Is BioLife Solutions profitable? | Yes, BioLife Solutions is EBITDA-positive (as of the last 12 months). |
What is the current EBITDA of BioLife Solutions? | BioLife Solutions's last 12 months EBITDA is $18.4M. |
What is BioLife Solutions's EBITDA margin? | BioLife Solutions's last 12 months EBITDA margin is 20%. |
What is the current EV/EBITDA multiple of BioLife Solutions? | Current EBITDA multiple of BioLife Solutions is 55.6x. |
What is the current FCF of BioLife Solutions? | BioLife Solutions's last 12 months FCF is $7.4M. |
What is BioLife Solutions's FCF margin? | BioLife Solutions's last 12 months FCF margin is 8%. |
What is the current EV/FCF multiple of BioLife Solutions? | Current FCF multiple of BioLife Solutions is 138.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.